Biotech research company
Location: South Korea
Employees: 11-50
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| - | Timefolio ... | timefolioc... |
| 05.07.2025 | Company K ... | kpartners.... |
Mentions in press and media 15
| Date | Title | Description |
| 26.12.2025 | ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly | - Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, ... |
| 11.12.2025 | NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO | Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer ca... |
| 05.11.2025 | Neok Bio Raises $75M in Series A Funding | Neok Bio, a Palo Alto, CA-based biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, raised $75M in Series A funding. The round was led by ABL Bio. The company... |
| 04.11.2025 | ABL spinout Neok exits stealth with $75M to take bispecific ADCs into the clinic | Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies including Sanofi, has in recent years paired its... |
| 29.10.2025 | I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform | New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned H... |
| 17.10.2025 | I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences | New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide Intention to pursue a H... |
| 07.04.2025 | ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases | - ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrie... |
| 05.10.2024 | The Next Frontier in Cancer Treatment: ABL Bio and TiumBio Forge Ahead with Innovative Therapies | In the relentless battle against cancer, two South Korean biopharmaceutical companies, ABL Bio and TiumBio, are making significant strides. Their recent announcements signal a promising future for patients grappling with advanced solid tumo... |
| 04.10.2024 | ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors | - MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase 1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies,... |
| 05.06.2024 | I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers | I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. Collaboration b... |
Show more